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Abstract
Most biological outcomes in a cell arise from a complex interplay between different cellular entities such as
proteins, DNA, RNA and metabolites. Therefore, a key challenge for biology in the twenty-first century is to
understand the structure and dynamics of the complex web of interactions in a cell that contribute to its proper
functioning. Recent years have seen a surge in the amount of “omics” data and an integration of several disciplines
which has influenced all areas of life sciences, from molecular biology to medicine. With the emergence of a number
of sophisticated tools and technologies as a result of genomics revolution, we are now in a position to view the
molecular aspects of diseases at a systems level by incorporating various cellular entities into a network framework.
Such systems/network-based approaches are not only enabling us to develop models of disease and wellness in a
population but also contributing to our efforts to reverse engineer the molecular networks corresponding to disease
states by perturbing using drug cocktails. These multi-scale personalized medicine approaches are likely to
significantly re-shape the health care industry in the coming decades and decrease the division that we currently see
between medicine and other biotechnology disciplines.
Keywords: Systems biology; Network pharmacology; Drug
discovery; Personal genomics; Patient profiling; Health care
Editorial
Reductionism, which has been the paradigm in biological research
for more than a century, has provided us with a wealth of knowledge
about the individual cellular components, their functions and
mechanisms. Despite its huge success in the last century, post-genomic
biology has increasingly made it clear that discrete biological function
can only rarely be attributed to an individual molecule. Instead, most
biological outcomes in a cell arise from a complex interplay between
different cellular entities such as proteins, DNA, RNA and metabolites.
Therefore, a key challenge for biology in the twenty-first century is to
understand the structure and dynamics of the complex web of
interactions in a cell that contribute to its proper functioning.
Although, we cannot answer this question in full in the very near
future, the analyses, concepts and frameworks that have resulted in the
recent years have provided the scientific community with tools to
interpret and better understanding the logic behind the several layers
of complex web of interactions happening in the cell.
In the last few years there has been a rapid development in various
high-throughput technologies which has led to the accumulation of a
large amount of data from different areas of molecular and cellular
biology. These developments together with increasing interest in the
community for gaining a systems-wide understanding of the cellular
machinery have provided us unprecedented insights into the structure,
organization and dynamics of various major cellular processes such as
transcription, translation, degradation, replication, metabolism etc.
Likewise, efforts to understand the interaction of the cell with external
environment have generated global phenotypic maps such as those
due to small-molecule perturbations [1] and human microbiomes,
which provide us with unparalleled information on the wide variety of
microbes which interact with the host’s tissues and play an important
role in health and disease of an individual [2-4]. Despite the growing
amount of data representing each of these processes it should be
admitted that none of these cellular processes work in isolation but
rather form an integrated network of different wiring diagrams which
is responsible for the observed behavior of the cell with in the context
of its environment. While there is mounting evidence from several
recent studies that each of these networks of associations associated
with a particular cellular process can be studied in detail to provide
meaningful insights into how they contribute to the functioning of the
cell, as well as to identify the factors that constrain their structure and
how they influence the genomes on which they are encoded, it is clear
that an open challenge of the contemporary biology is to integrate
these diverse cellular programs to first understand and model in
quantitative terms the topological and dynamic properties of such a
unified cellular network and then to exploit it for the therapeutic
benefit of mankind.
Conventional medicines that we are aware off today had a start as
empirical therapies based primarily in the context of physiology. Even
as mechanism-based therapies started to evolve, lack of efficacy and
adverse effects were noted and have been accepted to a certain extent.
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Most of the conventional medicines were developed as universal drugs
to all members of a population suffering from a particular disease. For
diseases with multiple pharmacotherapies, the choice was usually left
to the prescribing physician’s experience and preferences. In other
words, traditional molecular pathology has been performed by
analyzing well-characterized individual genes, proteins or other
molecules identified by targeted studies. However with recent
advances in genetics and our understanding of pharmacological
behavior of different drugs, it is evident that genetic variations among
individuals lead to differences in response to drugs and most complex
multi-gene associated diseases could be treated with different drugs
depending on the exact genetic variant responsible for the observed
phenotype seen in the population. In addition, conventional medicines
which were geared towards avoiding side-affects often result in adverse
effects despite extensive engineering and often lack efficacy [5]. All
these factors together with the observation that conventional clinical
trials usually fail for several newly developed drugs because they take
in statistical information about the general population of patients and
apply it to the individual, has resulted in the notion of personalized
medicine. In contrast to trial and error approach of conventional
therapies, personalized medicine aims to achieve a better match of
drugs to patients so that the right treatments are given to the right
patients at the right time. Personalized medicine has become a reality
with the sequencing of the human genome, advances in medical
genetics, and several technologies including medical diagnostics, single
nucleotide polymorphism (SNP) genotyping, transcriptomics and
proteomics. In case of complex disorders, the conventional ‘one-drug-
fits-all’ approach involves trial and error before an appropriate
treatment is found. In fact, even if appropriate treatment is found
using this approach, clinical trial data for a new drug merely show the
average response of a study group thereby limiting its success to a
small percentage of the population. This is because there is
considerable individual variation; some patients show no response
whereas others show a dramatic response. This has been increasingly
attributed to the fact that although approximately 99.9% of our DNA
sequence is identical, the 0.1% difference between any two individuals
is medically significant. Buried within this small percentage of
difference, lie the clues to hereditary susceptibility to virtually all
diseases. At the DNA level, this 0.1% difference translates into 3
million sites of genomic variation. In fact, studies of structural
variations (SV) in the human genome, indicate that differences
between individuals are far higher than 0.1% as a result of recent
sequencing of several human genomes from the HapMap and 1000
genomes projects [6,7]. Therefore, it is obvious that the concept of one
drug for all patients with the same disease does not hold and a more
individualized approach is needed. One critical aspect of most
complex diseases, for example breast cancer, is that the term
encompasses many different types of the disease – as defined by
differing combinations of disease-perturbed networks i.e, ensemble of
network variations can all be the cause of the same disease phenotype,
so the same drug might not work for these sub-types. Therefore, the
aim of the personalized medicine is to match the right drug to the
right patient and in some cases, even to design the treatment for a
patient according to genotype and other individual characteristics
causing the particular disease phenotype. Key to the use of these data,
and also a prime challenge, will be to mine and integrate these data in
the context of the dynamics of cellular networks and molecular
machines and to construct models of wellness and disease that are
predictive of possible disease outcomes so that appropriate action can
be taken before the onset of the disease. Recent technologies have
made this approach to drug discovery increasingly feasible. Genetic
variation between individual cells or populations can be studied using
SNP genotyping arrays or clone-based comparative genomic
hybridization (CGH) techniques. Changes in a cell’s entire
transcriptome or proteome can be profiled in detail. Integration of
networks encompassing interactions between different cellular entities
can then be studied within the framework of genetic and/or
transcriptomic variations responsible for these variations by
comparing at different levels; from cells, organs, tissues to individuals
to identify the nodes which are responsible for these changes. Detailed
changes in cellular phenotype can be quantitatively measured using
high content phenotypic screens and hence libraries of small
molecules, peptides or poly-nucleotides such as siRNA can be screened
to target specific cellular entities that need to be modulated in order to
revert the cellular state from a diseased to a healthy one (Figure 1) [5].
One clear advantage of this approach is that molecular entities
specific to the disease of interest can be perturbed while still affecting
connected pathways and networks [8]. The power of these
technologies lies in their ability to generate complex biological data at
massive scales. Integration and analysis of this multi-parametric data is
vital to personalized medicine. Patterns and relationships within these
data sets can be revealed using modelling and comparative network
analysis. These patterns can point to pathways that are relevant to
specific biological processes making the ultimate goal of
understanding the biology of a cell for therapeutic benefit, a reality at
the systems level.
Most current cancer therapies that target key molecules have not
fulfilled expected promises for common malignancies. Major
challenges include the incomplete understanding and validation of
these targets in patients, multiplicity and complexity of genetic and
epigenetic changes in majority of cancers, and the redundancies and
cross-talk found in key signaling pathways. Collectively, the uses of
single-pathway targeted approaches are not effective therapies for
human malignancies. To overcome these barriers, it is important to
understand the molecular cross-talk among key signaling pathways
and how they may be combinatorially altered by targeted agents. Such
strategies will aid the design of novel therapeutics and their
combinations against multifaceted diseases, in which efficacious
combination therapies will focus on altering multiple pathways rather
than single proteins- a goal of systems medicine, an important step
towards personalized approaches to medical treatments. In this
context, integrated network modeling and systems biology have
emerged as powerful tools benefiting our understanding of drug
mechanisms of action in real time.
Environmental factors can also play an important role in the cause
of a disease in an individual, who might otherwise be genetically
predisposed to it. Most differences in responses to drugs in human are
multifactorial, caused by genetic plus environmental factors and this is
yet another argument for the broader approach of personalized
medicine rather than limiting it to account for the genetic causes. For
instance, some adverse drug reactions are caused by interaction of the
drugs with environmental toxins, infectious organisms, or dietary
constituents. Therefore, prescription of drugs based on genotype tests
to individuals considered safe to receive the drugs, may not completely
eliminate the possibility of such a reaction. A patient matched to a
drug on the basis of a genotyping test may not necessarily respond to
it. Although there is considerable improvement in safety and efficacy
of a limited number of drugs available now in combination with
diagnostics, investigation of environmental factors must continue in
order to identify other factors, which will vary from one patient to
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another and would still come under the scope of personalized
medicine. One such environmental factor is the human intestinal
microflora composed of 1013 to 1014 microorganisms whose
collective genome (microbiome) contains at least 100 times as many
genes as the human genome [9].
Figure 1: A systems approach to identifying the molecular level causes of a particular disorder in a population. The approach involves
sampling population comprising of healthy (control group shown in green) and diseased group (shown in blue, along with those suffering
from a different disorder than that being studied - shown in red) suffering from a particular disease under study. The population is probed for
genetic variation, gene expression signature variation within the context of the various cellular networks which are perturbed in a diseased
group (and hence are responsible for the diseased phenotype) in order to identify the set of cellular entities which need to be modulated to
achieve a desired state representing a signature similar to the healthy individuals. Such a process can be iterative to identify the specific drugs
which can be functional and can be personalized to the individual to the extent of specific to particular tissues or organs the disease is bound
to occur.
The general consensus of the recent studies analyzing human
microbiomes is that humans are super organisms whose metabolism
represents an amalgamation of microbial and human attributes with
microbiomes between tissues and organs vastly varying with time,
although the genomic component of the humans remains the same
across the cell types further supporting the role of microbiomes in
shaping the state of an individual [3,4,9-11]. Without understanding
the interactions between human and microbial genomes, it is
impossible to obtain a complete picture of human biology. Therefore,
the next frontier in this field is the metagenomic analysis of human
microbiomes corresponding to different body parts in health and
disease as this has implications for clinical diagnosis and the treatment
of many human diseases associated with environmental microbial
influences. With the knowledge gained in this area, one can use
biomarkers to identify the bacterial population of the individual which
needs perturbation. Physicians can then manipulate the population
bacteria to be consistent with the optimal health of an individual. Such
an analysis would also identify bacteria that are resistant to certain
antibiotics, and enable the selection of the appropriate antibiotic for a
patient. For instance, in the future, healthy individuals could undergo
a metagenomic analysis of their gut to determine their immune status
and susceptibility to certain diseases. Such an analysis may enable the
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assessment of the effects of age, diet and diseases such as inflammatory
bowel disease, cancer, obesity and bacterial vaginosis on the microbial
flora of the body parts in persons living in different environments with
different dietary habits. In fact, consortiums such as the Human
Microbiome Project (HMP) [12] aim to generate resources to describe
these microbial communities and to analyze their role in health and
disease. For instance, HMP has already proven to be very effective by
sequencing and making it public the microbiomes of more than 15
body habitats for 300 healthy human volunteers, providing a wealth of
information for understanding the differences between different body
parts across individuals. Such datasets not only allow the identification
of bacterial species and their interplay in an ecosystem context,
responsible for maintaining a homeostasis in the respective body parts
but also permit dissecting their role in non-genetic diseases in
unhealthy patients, providing a wealth of opportunities for network
analysis and integration in the context of human-microbiome
associations and more generally their relevance in the context of
personalized medicine as more data becomes available.
Personalized medicine is a challenge because each of our genomes
differ by approximately 6 million bases, this large difference in
individuals ultimately requires the use of the patient’s own baseline
healthy data as a ‘control’ that can then be used for subtractive
analyses of longitudinal accumulations of molecular and cellular
information that signal the transitions from wellness to disease. Such a
medicine can become a reality as the details of disease-perturbed
molecular networks open the possibility of using drugs targeted at key
nodes to stop disease progression. In other words, network-based view
of drug discovery and development seeks to define disease states as
molecular networks which integrate the following major aspects 1)
Gene expression profiles 2) Genome-wide association data reflecting
the genomic variations among populations 3) integrated interaction
networks which amalgamate the associations between genes, proteins,
RNA, cellular metabolites etc. The complex cellular network of
interactions are then compared between diseased and healthy
populations at the level of cells, tissues or organs, informed by the
DNA variation and gene expression patterns to identify one or more of
the cellular entities responsible for the rewiring patterns seen in the
disease phenotype (Figure 1). Such an approach takes into account the
multi-factorial nature of most complex disorders and identifies the
part of the diseased state (network) which needs to be perturbed
(perhaps combinatorially) with possible combinations of drugs to get
back to the desired healthy state. For instance, in complex diseases
such as cancer which are known to be caused by a wide variety of
phenomenon, the future of personalized medicine is to have a large
number of drugs to choose from, each associated with one or more
biomarkers that predict responsiveness to the particular sub-type
under study in a patient. For example, ~15-20% of breast cancers have
HER2 amplification, which corresponds to high levels of
responsiveness to trastuzumab [13,14]. Without knowing the relevant
population of breast cancer patients to treat with this inhibitor, the
drug would not have had significant improvement in the overall
population. However, even when we use available tools to predict
patient sensitivity, such as FISH for HER2 amplification, we still are
not able to perfectly predict who will respond. As an example,
approximately one third breast cancer patients with amplified HER2
do not respond to trastuzumab, in part due to deregulation of
downstream or parallel pathway components such as PTEN or P13K
[15,16]. It is in this context the integrated framework of genetic
variation, gene expression profiling and network analysis can provide
a huge advantage to uncover the patient population which is likely to
respond to appropriate drug cocktails. Personalized medicine is
catalyzing a transformation of medicine that promises to deal with the
current impenetrable barriers of incredible complexities of disease
through systems approaches, emerging technologies and powerful
analytical tools. The ultimate promise is that the focus of medicine will
be shifted from disease, which is currently based on physiology and
phenotypes, to that of wellness, where signatures of population with
healthy states corresponding to billions of data points for each
individual will define with exquisite specificity the nature of their
wellness – and any transitions into disease can be identified as early as
possible to prevent the onset of the disease. Central to this view is the
idea that the molecular, cellular and phenotypic data of eventually
hundreds of millions of patients will be available for systems analyses
which will allow the integration, mining and development of
predictive models of each disease. Such a concept of shared patient
data and disease models not only help to continuously refine existing
disease maps built in an open-access manner that includes researchers
from around the world but also can fundamentally change the speed of
the discovery and development of therapies for new diseases.
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